|
Meca-Lallana JE, Oreja-Guevara C, Munoz D, Olascoaga J, Pato A, Ramio-Torrenta L, Meca-Lallana V, Hernandez MA, Marzo ME, Alvarez-Cermeno JC, Rodriguez-Antiguedad A, Montalban X, Fernandez O; Spanish GILENYA Registry Investigators. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021. PubMed PMID: 34644366; PubMed Central PMCID: PMC8513911.
AÑO: 2021; IF: 3.752
|
34644366
|
Fernandez-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Gascon-Gimenez F, Sainz de la Maza S, Walo-Delgado PE, Maceski A, Rodriguez-Martin E, Roldan E, Villarrubia N, Saiz A, Blanco Y, Sanchez P, Carreon-Guarnizo E, Aladro Y, Brieva L, Iniguez C, Gonzalez-Suarez I, Rodriguez de Antonio LA, Masjuan J, Costa-Frossard L, Villar LM. Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021 Jan 6;8(2):e940. doi: 10.1212/NXI.0000000000000940. Print 2021 Mar 4. PubMed PMID: 33408167; PubMed Central PMCID: PMC7862094.
AÑO: 2021; IF: 11.36
|
|
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Haring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. PubMed PMID: 32757523.
AÑO: 2020; IF: 91.245
|
|
Meca-Lallana J, Maurino J, Hernandez-Perez MA, Sempere AP, Brieva L, Garcia-Arcelay E, Terzaghi M, Saposnik G, Ballesteros J. Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective. Neurol Ther. 2020 Jun;9(1):173-179. doi: 10.1007/s40120-020-00176-6. Epub 2020 Jan 18. PubMed PMID: 31955391; PubMed Central PMCID: PMC7229098.
AÑO: 2020
|
|
Fuentes-Rumi L, Hernandez-Clares R, Carreon-Guarnizo E, Valero-Lopez G, Iniesta-Martinez F, Cabrera-Maqueda JM, Leon-Hernandez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord. 2020 Sep;44:102311. doi: 10.1016/j.msard.2020.102311. Epub 2020 Jun 20. PubMed PMID: 32593958.
AÑO: 2020; IF: 4.339
|